Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2022-04-24 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
中源协和细胞基因工程股份有限公司2021年度内部控制审计报告
Regulatory Filings
2022-04-24 Chinese
中源协和细胞基因工程股份有限公司2021年度募集资金存放与实际使用情况鉴证报告
Regulatory Filings
2022-04-24 Chinese
中源协和细胞基因工程股份有限公司独立董事对公司对外担保情况及关联方占用资金情况的专项说明和独立意见
Audit Report / Information Classification · 95% confidence The document is a special statement and independent opinion by independent directors regarding the company's external guarantees and related party fund occupation during the reporting period. It references regulatory requirements from the China Securities Regulatory Commission and discusses compliance with laws and company articles of association. The document includes detailed explanations and opinions but does not contain financial statements or quarterly/yearly financial data. It is a standalone audit-related statement focusing on compliance and internal control matters rather than a full annual report or interim report. The document length is short (1560 characters), but it is not merely an announcement or certification; it provides substantive independent directors' opinions on specific regulatory compliance issues. Therefore, it fits best under Audit Report / Information (AR).
2022-04-24 Chinese
中源协和细胞基因工程股份有限公司2022年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2022 年第一季度报告" which translates to "2022 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on shareholder information. The report explicitly states it is unaudited and covers the first quarter of 2022, indicating it is a quarterly financial report. The length of the document (13,283 characters) and the presence of substantive financial data confirm it is a full interim/quarterly report rather than a brief announcement or summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2022-04-24 Chinese
中源协和细胞基因工程股份有限公司董事会审计委员会2021年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "Board of Directors Audit Committee 2021 Annual Performance Report" of Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It details the audit committee's activities during 2021, including meetings held, supervision and evaluation of the external audit firm, internal audit guidance, review of financial reports, internal control evaluation, and coordination with management and auditors. The document is a report on the audit committee's duties and activities rather than the audit report itself or the full annual report. It does not contain full financial statements or detailed audit results but summarizes the committee's oversight and evaluation work. This fits the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and related information excluding full annual reports. The document length is 2223 characters, which is consistent with a detailed committee report but not a full annual report. Therefore, the appropriate classification is AR with high confidence.
2022-04-24 Chinese
中源协和细胞基因工程股份有限公司独立董事关于计提资产减值损失的独立意见
Audit Report / Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding the company's decision to recognize an asset impairment loss. It references compliance with accounting standards and company governance rules. The document is short (581 characters) and primarily contains the independent directors' certification or attestation about the impairment decision. It does not contain detailed financial statements or comprehensive financial data. This fits the profile of an audit-related opinion or certification rather than a full audit report or annual report. Given the nature of the document as an independent directors' opinion on an accounting matter, it aligns best with the Audit Report / Information (AR) category, which includes standalone audit reports and applied accounting principles. Confidence is high due to clear references to accounting standards and the independent directors' formal opinion.
2022-04-24 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.